NewAmsterdam Pharma (NAMS) Receivables - Other (2021 - 2026)
NewAmsterdam Pharma (NAMS) posted Receivables - Other of $8.0 million for Q1 2026, up 18.48% sequentially from $6.8 million in Q4 2025, and up 455.83% YoY from $1.4 million in Q1 2025.
NewAmsterdam Pharma (NAMS) Receivables - Other (2021 - 2026) Analysis & Trends
NewAmsterdam Pharma has reported Receivables - Other for 5 years, with the latest figure at $8.0 million in Q1 2026.
- Quarterly Receivables - Other rose 455.83% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 million (up 455.83% YoY) and the FY2025 annual result came in at $6.8 million, up 287.01% from the prior year.
- Receivables - Other climbed to $8.0 million in Q1 2026 per NAMS's latest filing, from $6.8 million in the prior quarter.
- Over five years, Receivables - Other peaked at $8.0 million in Q1 2026 and troughed at $875000.0 in Q4 2023.
- A 4-year average of $3.4 million and a median of $2.7 million in 2024 frame the typical range for Receivables - Other.
- The sharpest annual moves came in 2025 and 2026: Receivables - Other slumped 63.81% in 2025, then soared 455.83% in 2026.
- Over 4 years, Receivables - Other stood at $875000.0 in 2023, then jumped by 99.77% to $1.7 million in 2024, then jumped by 287.01% to $6.8 million in 2025, then advanced by 18.48% to $8.0 million in 2026.
- According to Business Quant data, Receivables - Other over the past three periods registered $8.0 million, $6.8 million, and $3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | NewAmsterdam Pharma | 3.17 Bn | 3.17 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.11 Mn |
| Jun 30, 2026 | 5.11 Mn |
| Mar 31, 2026 | 8.02 Mn |
| Mar 31, 2026 | 8.02 Mn |
| Dec 31, 2025 | 6.77 Mn |
| Dec 31, 2025 | 6.77 Mn |
| Sep 30, 2025 | 3.90 Mn |
| Sep 30, 2025 | 3.90 Mn |
| Jun 30, 2025 | 3.29 Mn |
| Jun 30, 2025 | 3.29 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Mar 31, 2025 | 1.44 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Dec 31, 2024 | 1.75 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Sep 30, 2024 | 1.65 Mn |
| Jun 30, 2024 | 2.13 Mn |
| Jun 30, 2024 | 2.13 Mn |
| Mar 31, 2024 | 3.99 Mn |
| Mar 31, 2024 | 3.99 Mn |